; and (cc) documents in the clinical record of the hospice patient that the written policies and procedures were provided and discussed; and (III) at the time when an employee of the hospice program assists in the disposal of controlled substances of a hospice patient, documents in the clinical record of the hospice patient all disposed controlled substances. . (b) Guidance Not later than 90 days after the date of enactment of this Act, and after providing notice and opportunity for public comment, the Attorney General shall issue guidance to hospice programs to assist the programs in satisfying the requirements under paragraph (5) of section 302(g) of the Controlled Substances Act ( 21 U.S.C. 822(g) ), as added by subsection (a). 3. GAO study and report on hospice safe drug management (a) Study (1) In general The Comptroller General of the United States (in this section referred to as the Comptroller General ) shall conduct a study on the requirements applicable to and challenges of hospice programs with regard to the management and disposal of controlled substances in the home of an individual. (2) Contents In conducting the study under paragraph (1), the Comptroller General shall include— (A) an overview of challenges encountered by hospice programs regarding the disposal of controlled substances, such as opioids, in a home setting, including any key changes in disposal of controlled substances over time; and (B) a description of Federal requirements, including requirements under the Medicare program, for hospice programs regarding the disposal of controlled substances in a home setting, and oversight of compliance with those requirements. (b) Report Not later than 18 months after the date of enactment of this Act, the Comptroller General shall submit to Congress a report containing the results of the study conducted under subsection (a), together with recommendations, if any, for such legislation and administrative action as the Comptroller General determines appropriate.